Wednesday, March 1, 2017

Muse bio Finds $23M For Gene Editing Technology

Boulder-based Muse bio, a company developing gene editing technology, said on Tuesday that it has raised $23M in a Series B financing round. The funding was led by Venrock, and also included Foresite Capital, Paladin Capital, NanoDimension, and Spruce/MLS. The company said the funds will go to advance development of its gene editing and single-cell writing technology. Kevin Ness is CEO of Muse bio. More information »